Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Outset Medical, with one sell, one hold and three buy recommendations. The average 12-month price target is $10.00, versus the stock’s reported $4.50 price.
• Outset Medical reported a quarterly loss of $0.80 per share, missing the $0.72 consensus estimate, though revenue of $31.64 million exceeded expectations of $28.97 million. Analysts expect a full-year loss of $3.82 per share.
• Shares have fallen 6.6% and trade near $4.50, while hedge funds including Renaissance Technologies and BML Capital Management increased their holdings. CFO Renee Gaeta sold shares to cover tax withholding obligations, and insiders sold $115,660 of stock over the past quarter.

Shares of Outset Medical, Inc. (NASDAQ:OM - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $10.00.

OM has been the topic of several recent research reports. TD Cowen reaffirmed a "buy" rating on shares of Outset Medical in a research note on Friday, May 8th. Weiss Ratings raised shares of Outset Medical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 7th.

Insider Activity

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of the company's stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the transaction, the chief financial officer owned 113,753 shares of the company's stock, valued at approximately $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 25,337 shares of company stock valued at $115,660 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Outset Medical

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in shares of Outset Medical in the 2nd quarter valued at $121,000. Marquette Asset Management LLC purchased a new position in Outset Medical in the 2nd quarter worth about $212,000. Renaissance Technologies LLC raised its holdings in Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company's stock worth $853,000 after buying an additional 176,870 shares during the period. Sei Investments Co. raised its holdings in Outset Medical by 15.5% during the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company's stock worth $136,000 after buying an additional 4,738 shares during the period. Finally, BML Capital Management LLC lifted its stake in Outset Medical by 250.2% during the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company's stock valued at $7,304,000 after buying an additional 1,359,021 shares in the last quarter.

Outset Medical Trading Down 6.6%

Shares of OM stock opened at $4.50 on Thursday. The stock has a 50-day simple moving average of $4.59 and a 200 day simple moving average of $4.26. The stock has a market capitalization of $84.60 million, a P/E ratio of -1.10 and a beta of 1.96. Outset Medical has a fifty-two week low of $3.00 and a fifty-two week high of $16.16. The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87.

Outset Medical (NASDAQ:OM - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 58.06% and a negative net margin of 63.06%.The business had revenue of $31.64 million during the quarter, compared to the consensus estimate of $28.97 million. On average, sell-side analysts expect that Outset Medical will post -3.82 earnings per share for the current fiscal year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source